title: Lenalidomide: patient management strategies.
abstract: Experience with thalidomide has underscored the need for diligent monitoring and management of side effects to achieve optimal therapeutic benefit. Initial phase II and III results with lenalidomide, a thalidomide analogue, have confirmed impressive response rates with a significantly more favorable toxicity profile. The Cleveland Clinic experience with lenalidomide alone or in combination with pegylated liposomal doxorubicin, vincristine, and reduced schedule dexamethasone will be described. Peripheral neuropathy and deep venous thrombosis (DVT). Low-dose aspirin alleviated DVT when lenalidomide was used in combination with anthracycline-containing chemotherapy. Strategies for managing these toxicities and for recognition and management of lenalidomide-associated myelosuppression are reviewed.
authors.affiliation: Multiple Myeloma Research Program, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA. husseim@ccf.org
authors.forename: Mohamad A
authors.initials: MA
authors.lastname: Hussein
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy*; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D013792:Thalidomide; D000077269:Lenalidomide